Keywords: AstraZeneca, Emerging markets, Branded generics

AstraZeneca turns further to emerging markets, aiming for quarter of its revenues from these by 2014

Article | 17 March 2010

Anglo-Swedish drug major AstraZeneca is increasing its focus on the world’s emerging markets to sustain its growth over the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in